CANY
CCXI

Caxton Associates (New York)’s ChemoCentryx, Inc. CCXI Stock Holding History

Caxton Associates (New York)’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,783
Closed -$273K – 677
2020
Q1 		$273K Buy
+6,783
New +$288K 0.05% 281

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Caxton Associates (New York)'s CCXI Position: Q2 2020 in Review

Caxton Associates (New York) sold out of ChemoCentryx, Inc. (CCXI) in Q2 2020, closing a stake of 6,783 shares — an estimated $273K sold.

Caxton Associates (New York) first reported a position in CCXI in Q1 2020 and held it in 1 quarter. The position peaked at $273K in Q1 2020. 193 funds tracked by Wall St. Rank hold CCXI as of Q2 2020.

  • Caxton Associates (New York) reported no remaining ChemoCentryx, Inc. position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,783 ChemoCentryx, Inc. shares in Q2 2020, an estimated $273K.
  • Caxton Associates (New York) first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s ChemoCentryx, Inc. position peaked at $273K in Q1 2020.
  • 193 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.